Izafe Group Ab · OMXSTO:IZAFE_B
Izafe Group Ab — Q3 2025 Earnings Presentation
22 slides from Izafe Group Ab's earnings presentation, Nov 3, 2025
Slide 1: Quarterly Report Third Quarter 2025
Quarterly Report Third Quarter 2025
Slide 2: About iZafe Group
About iZafe Group iZafe Group is a Life-Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management in the home. The company leads the development of digital drug dispensing through the pharmaceutical robot Dosell and th
Slide 3: Comments from CEO
Comments from CEO We enter the final quarter of the year with strong momentum, rapid growth, and a business model now fully built on recurring revenues. Revenue now consists entirely of subscription income, providing stability, predictability, and scalability as the number of active Dosell units con
Slide 4: Comments from CEO
Comments from CEO Looking Ahead – Strong Growth and Increasing Cash Flows We stand stronger than ever. Our growth is now entirely driven by recurring revenues, our business model is proven to be scalable, and we have established a solid foundation across multiple markets. Going forward, our focus is
Slide 5: Company overview
Company overview Increased adherence is important for the pharmaceutical industry iZafe Group also offers the digital platform Pilloxa, which – iZafe Group develops and commercializes digital products through a mobile app, cloud platform, and smart hardware and services that ensure people take the r
Slide 6: Dosell – safe medication at home
Dosell – safe medication at home Digital medication-dispensing robot that ensures the right medicine at the right time Dosell is a Swedish-developed medical device that automatically reminds and dispenses the correct dose of medication at the right time. The product is primarily used at home and in
Slide 7: Pilloxa
Pilloxa SaaS platform for digital patient support programs (Patient Support Programs) Pilloxa is a Swedish-developed, regulatory-approved SaaS platform that enables pharmaceutical companies to digitalize their Patient Support Programs (PSPs). Through a combination of a mobile app, cloud platform, an
Slide 8: Key figures
Key figures THE GROUP 2025 2024 2025 2024 2024 TSEK Jul-Sept Jul-Sept Jan-Sept Jan-Sept Jan-Dec Net sales 1 102 2 031 3 556 5 609 7 954 Operating result (EBIT) -3 273 -4 148 -11 069 -13 728 -19 425 Operating result before depreciation and -2 297 -3 166 -8 130 -10 781 -15 495 amortization (EBITDA) Pr
Slide 9: Financial overview
Financial overview THE GROUP TURNOVER AND RESULTS, JULY-SEPTEMBER 2025 TURNOVER AND RESULTS, JANUARY-SEPTEMBER 2025 Net sales for the quarter amounted to 1,102 TSEK (2,031) and consisted entirely of recurring license revenues, as no hardware sales were Net revenue for the period amounted to 3,556 TS
Slide 10: Financial position, cash flow and liquidity
FINANCIAL POSITION, CASH FLOW AND LIQUIDITY INVESTMENTS AND DEVELOPMENT EXPENDITURE Cash flow from operating activities amounted to -2,890 TSEK Investments during the quarter amounted to 180 TSEK (-2,913). The company’s cash flow from operating activities is (180), primarily related to capitalized d
Slide 11: Condensed income statement
Condensed income statement GROUP TSEK 2025 2024 2025 2024 2024 Jul-Sept Jul-Sept Jan-Sept Jan-Sept Jan-Dec Operating income Net sales 1 102 2 031 3 556 5 609 7 954 Other operating income 407 396 1 234 1 189 1 602 Total revenue 1 509 2 427 4 790 6 798 9 556 Operating costs Goods for resale -527 -2 06
Slide 12: Condensed statement of financial position
Condensed statement of financial position GROUP TSEK 2025 2024 2024 30-Sept 30-Sept 31-Dec ASSETS Non-current assets Balanced development expenditure 14 761 16 839 16 405 Customer agreements 10 559 0 0 Other intangible assets 7 32 26 Tangible fixed assets 4 172 64 47 Right-of-use assets 251 1 257 1
Slide 13: Condensed statement of changes in equity
Condensed statement of changes in equity GROUP TSEK 2025 2024 2025 2024 2024 Jul-Sept Jul-Sept Jan-Sept Jan-Sept Jan-Dec Equity, opening balane 10 344 20 591 9 728 25 353 25 353 Total result The result of the period -3 537 -4 955 -11 819 -14 601 -20 509 Transactions with owners New share issue 10 00
Slide 14: Condensed statement of cash flows
Condensed satement of cash flows GROUP TSEK 2025 2024 2025 2024 2024 Jul-Sept Jul-Sept Jan-Sept Jan-Sept Jan-Dec Operating profit/loss -3 273 -4 148 -11 069 -13 728 -19 425 Adjustments for non-cash items 976 982 2 939 2 947 4 242 Interest received, etc. 0 0 0 0 39 Interest paid, etc. -264 -709 -750
Slide 15: Distribution of revenues
Distribution of revenues GROUP TSEK 2025 2024 2025 2024 2024 Jul-Sept Jul-Sept Jan-Sept Jan-Sept Jan-Dec Dosell 1 039 1 965 3 363 5 349 7 628 Pilloxa 63 66 193 260 326 Total 1 102 2 031 3 556 5 609 7 954 iZafe Group AB iZafe Group Org.no: AB 556762–3391 Org.no:report Interim 556762–3391 October-Dece
Slide 16: Reporting by business segment
Reporting by business segment GROUP TSEK 2025 2024 2025 2024 2024 Jul-Sept Jul-Sept Jan-Sept Jan-Sept Jan-Dec External revenue Dosell 1 039 1 965 3 363 5 349 7 628 Pilloxa 63 66 193 260 326 1 102 2 031 3 556 5 609 7 954 Direct costs Dosell -527 -2 063 -2 272 -5 912 -9 588 Pilloxa 0 0 0 0 0 -527 -2 0
Slide 17: Acquisition analysis
Acquisition analysis On 30 September 2025, iZafe Group AB acquired 100% of the outstanding shares in its exclusive distributor in the Netherlands, Thuisapparatuur Nederland B.V. The purchase price amounted to 7,728 TSEK, in addition to iZafe assuming an existing loan of 9,409 TSEK, bringing the tota
Slide 18: Condensed income statement – Parent company
Condensed income statement PARENT COMPANY TSEK 2025 2024 2025 2024 2024 Jul-Sept Jul-Sept Jan-Sept Jan-Sept Jan-Dec Operating income Net sales 450 450 1 350 1 357 1 809 Other operating income 405 396 1 210 1 189 1 586 Total revenue 855 846 2 560 2 546 3 395 Operating costs Other external expenses -1
Slide 19: Condensed balance sheet – Parent company
Condensed balance sheet PARENT COMPANY TSEK 2025 2024 2024 30-Sept 30-Sept 31-Dec ASSETS Non-current assets Tangible fixed assets 4 54 41 Financial fixed assets 42 723 32 000 34 675 Current assets Current receivables 16 225 9 995 764 Cash and bank balances 1 877 2 710 408 Total assets 60 829 44 759
Slide 20: Accounting principles, risks, and other information
Accounting principles, risks, and other information. NOTE 1. COMPANY INFORMATION The group’s operations include the development and marketing of products that contribute to a more qualitative and secure healthcare at home, both in the Swedish and international markets. The group develops and sells t
Slide 21: Note 8. Options and convertible loan
NOTE 8. OPTIONS AND CONVERTIBLE LOAN The group has three outstanding stock option programs. TO11 - Incentive program for certain employees Each TO11 option entitles the holder to subscribe for one (1) new Series B share in the Company against cash payment equivalent to 200 percent of the volume-weig
Slide 22: Contact
AUDIT REVIEW This report has not been subject to review by the auditor of iZafe Group. CERTIFIED ADVISER DNB Carnegie UPCOMING FINANCIAL REPORTS 2026-02-16 2025 Year-End Report 2026-04-28 2026 Interim report Q1 2026-05-01 2025 Annual report 2026-09-01 2026 Interim report Q2 2026-11-03 2026 Interim r